Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

Investing in healthcare

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology. The technology helps bio drugs overcome intracellular barriers, making them more effective. Defence is excited about three upcoming clinical trials, expected to start by the end of the year, which will be important for the company's growth. Defence is also actively working to license their technology to other companies. The mRNA therapeutics market is projected to reach close to $130 billion by 2030, making the potential for Defence's growth promising.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

‍